Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda®
Abstract Background and Objective Biological medicinal products improve patients’ lives, but access is limited, mainly due to high costs. Patents for many existing biological products are expiring, and generic versions, which are referred to as biosimilars, are produced to serve as an alternative to...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Adis, Springer Healthcare
2024-09-01
|
| シリーズ: | Drugs in R&D |
| オンライン･アクセス: | https://doi.org/10.1007/s40268-024-00485-3 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|